Literature DB >> 11447337

Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor.

H Jongsma1, L M Pettersson, M K Reimer, M Kanje, A Waldenström, F Sundler, N Danielsen.   

Abstract

The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has been proposed to have a role in nociception. Here we have used the formalin test, thermal laser stimulation and mechanical von Frey stimulation to investigate possible alteration of PAC1-/- mice nociceptive behaviour. Our finding, that PAC1-/- mice have a substantial, 75% decrease in nociceptive response during the late phase, provides clear evidence that the specific PACAP-receptor PAC1 is involved in the mediation of nociceptive responses during chronic conditions such as inflammation. PAC1-/- mice had small or no changes in the response to mechanical and thermal laser stimulation. This suggests a limited, if any, involvement of PAC1 in nociception after short-lasting stimuli. Injury-induced changes in DRG neuropeptide expression were more pronounced in PAC1-/- mice, implying neuroregulatory functions of PAC1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447337     DOI: 10.1097/00001756-200107200-00034

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  In search of analgesia: emerging roles of GPCRs in pain.

Authors:  Laura S Stone; Derek C Molliver
Journal:  Mol Interv       Date:  2009-10

Review 3.  Bladder sensory physiology: neuroactive compounds and receptors, sensory transducers, and target-derived growth factors as targets to improve function.

Authors:  Eric J Gonzalez; Liana Merrill; Margaret A Vizzard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-04-23       Impact factor: 3.619

Review 4.  Pituitary adenylate cyclase activating polypeptide in stress-related disorders: data convergence from animal and human studies.

Authors:  Sayamwong E Hammack; Victor May
Journal:  Biol Psychiatry       Date:  2014-12-09       Impact factor: 13.382

Review 5.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 6.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 7.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

8.  Parabrachial Pituitary Adenylate Cyclase-Activating Polypeptide Activation of Amygdala Endosomal Extracellular Signal-Regulated Kinase Signaling Regulates the Emotional Component of Pain.

Authors:  Galen Missig; Linda Mei; Margaret A Vizzard; Karen M Braas; James A Waschek; Kerry J Ressler; Sayamwong E Hammack; Victor May
Journal:  Biol Psychiatry       Date:  2016-08-29       Impact factor: 13.382

9.  Parabrachial nucleus (PBn) pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the amygdala: implication for the sensory and behavioral effects of pain.

Authors:  Galen Missig; Carolyn W Roman; Margaret A Vizzard; Karen M Braas; Sayamwong E Hammack; Victor May
Journal:  Neuropharmacology       Date:  2014-07-03       Impact factor: 5.250

Review 10.  Role of PACAP in ischemic neural death.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2008-05-16       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.